Adam L. Rothman MD , Flavius A. Beca MD , Jonathan D. Tijerina MD , Darren M. Schuman BS , Richard K. Parrish II MD , Elizabeth A. Vanner PhD , Katy C. Liu MD, PhD
{"title":"老年性黄斑变性患者使用和不使用抗血管内皮生长因子的青光眼导管疗效。","authors":"Adam L. Rothman MD , Flavius A. Beca MD , Jonathan D. Tijerina MD , Darren M. Schuman BS , Richard K. Parrish II MD , Elizabeth A. Vanner PhD , Katy C. Liu MD, PhD","doi":"10.1016/j.ogla.2024.01.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF.</p></div><div><h3>Design</h3><p>Retrospective clinical cohort study.</p></div><div><h3>Participants</h3><p>Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded.</p></div><div><h3>Methods</h3><p>A Kaplan–Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) > 21 mmHg or < 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP > 21 mmHg within 3 months of surgery after a reduction to < 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (< 1 year) and late (> 1 year) complications were compared through 5 years.</p></div><div><h3>Main Outcome Measures</h3><p>Survival analysis, IOP, number of medications.</p></div><div><h3>Results</h3><p>Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (<em>P</em> = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (<em>P</em> = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, <em>P</em> = 0.05), greater IOP reduction (60% vs. 49%, <em>P</em> = 0.04), fewer medications (1.2 vs. 2.1, <em>P</em> = 0.02), and more complete success (50% vs. 15%, <em>P</em> = 0.001) at final follow-up (32 vs. 36 months, <em>P</em> = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], <em>P</em> = 0.04). There were no significant differences in early or late complications.</p></div><div><h3>Conclusions</h3><p>Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery.</p></div><div><h3>Financial Disclosure(s)</h3><p>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 3","pages":"Pages 260-270"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration\",\"authors\":\"Adam L. Rothman MD , Flavius A. Beca MD , Jonathan D. Tijerina MD , Darren M. Schuman BS , Richard K. Parrish II MD , Elizabeth A. Vanner PhD , Katy C. Liu MD, PhD\",\"doi\":\"10.1016/j.ogla.2024.01.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF.</p></div><div><h3>Design</h3><p>Retrospective clinical cohort study.</p></div><div><h3>Participants</h3><p>Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded.</p></div><div><h3>Methods</h3><p>A Kaplan–Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) > 21 mmHg or < 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP > 21 mmHg within 3 months of surgery after a reduction to < 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (< 1 year) and late (> 1 year) complications were compared through 5 years.</p></div><div><h3>Main Outcome Measures</h3><p>Survival analysis, IOP, number of medications.</p></div><div><h3>Results</h3><p>Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (<em>P</em> = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (<em>P</em> = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, <em>P</em> = 0.05), greater IOP reduction (60% vs. 49%, <em>P</em> = 0.04), fewer medications (1.2 vs. 2.1, <em>P</em> = 0.02), and more complete success (50% vs. 15%, <em>P</em> = 0.001) at final follow-up (32 vs. 36 months, <em>P</em> = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], <em>P</em> = 0.04). There were no significant differences in early or late complications.</p></div><div><h3>Conclusions</h3><p>Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery.</p></div><div><h3>Financial Disclosure(s)</h3><p>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p></div>\",\"PeriodicalId\":19519,\"journal\":{\"name\":\"Ophthalmology. Glaucoma\",\"volume\":\"7 3\",\"pages\":\"Pages 260-270\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Glaucoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2589419624000103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589419624000103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration
Purpose
To compare glaucoma tube outcomes of wet age-related macular degeneration (AMD) eyes receiving anti-VEGF injections versus dry AMD eyes and no anti-VEGF.
Design
Retrospective clinical cohort study.
Participants
Patients with wet AMD and a history of anti-VEGF within a year prior or after stand-alone glaucoma tube surgery and eyes with dry AMD and no history of anti-VEGF with at least 6 months of follow-up. Eyes with neovascular glaucoma or anti-VEGF for reason other than wet AMD were excluded.
Methods
A Kaplan–Meier analysis compared survival for wet versus dry AMD eyes. Failure was defined as intraocular pressure (IOP) > 21 mmHg or < 20% IOP reduction from baseline or IOP ≤ 5 mmHg for 2 consecutive postoperative visits starting at month 3, additional glaucoma surgery, or no light perception. Complete success was defined as no failure or medications at final follow-up. Hypertensive phase was defined for valved tubes as IOP > 21 mmHg within 3 months of surgery after a reduction to < 22 mmHg during the first postoperative week. Intraocular pressure, percent reduction in IOP, number of glaucoma medications, and early (< 1 year) and late (> 1 year) complications were compared through 5 years.
Main Outcome Measures
Survival analysis, IOP, number of medications.
Results
Baseline IOP, number of medications, or tube type were not significantly different between wet (n = 24) and dry AMD eyes (n = 54). No wet AMD eyes failed versus 10 (18%) dry AMD eyes (P = 0.03). Five-year survival was estimated as 100% for wet AMD and 72% for dry AMD (P = 0.04). Wet AMD eyes had lower IOP (10.6 vs. 12.7 mmHg, P = 0.05), greater IOP reduction (60% vs. 49%, P = 0.04), fewer medications (1.2 vs. 2.1, P = 0.02), and more complete success (50% vs. 15%, P = 0.001) at final follow-up (32 vs. 36 months, P = 0.42). Fewer wet than dry AMD eyes experienced hypertensive phase (0/10 [0%] vs. 4/10 [40%], P = 0.04). There were no significant differences in early or late complications.
Conclusions
Exposure to anti-VEGF may influence postoperative wound healing and capsule formation which may improve glaucoma tube surgical outcomes. Prospective data is needed to consider perioperative administration of anti-VEGF for glaucoma tube surgery.
Financial Disclosure(s)
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.